• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Abvc Biopharma Inc (NQ: ABVC )

    1.280 -0.120 (-8.57%)
    Streaming Delayed Price Updated: 3:28 PM EDT, Apr 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 640,797
    Open 1.340
    Bid (Size) 1.260 (22)
    Ask (Size) 1.280 (6)
    Prev. Close 1.400
    Today's Range 1.260 - 1.410
    52wk Range 0.6739 - 9.470
    Shares Outstanding 24,420,526
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga

    Performance

    YTD
    +6.67%
    +6.67%
    1 Month
    -6.57%
    -6.57%
    3 Month
    -7.91%
    -7.91%
    6 Month
    +5.79%
    +5.79%
    1 Year
    -82.23%
    -82.23%

    More News

    Read More
    AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
    Via TheNewswire.com
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
    Via NewMediaWire
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
    Via NewMediaWire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
    Via NewMediaWire
    ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
    Via TheNewswire.com
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Why ABVC BioPharma Stock Is Up Today
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
    Via NewMediaWire
    ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
    Via TheNewswire.com
    AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars
    Via NewMediaWire
    AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars
    Via TheNewswire.com
    ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
    Via NewMediaWire
    Topics Intellectual Property
    Exposures Intellectual Property
    ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
    Via TheNewswire.com
    Topics Intellectual Property
    Exposures Intellectual Property
    ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
    Via NewMediaWire
    ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
    Via TheNewswire.com
    ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars
    Via NewMediaWire
    ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars
    Via TheNewswire.com
    ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues
    Via NewMediaWire
    ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
    Via TheNewswire.com
    Topics Intellectual Property
    Exposures Intellectual Property
    ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
    Via NewMediaWire
    Topics Intellectual Property
    Exposures Intellectual Property
    ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
    Via NewMediaWire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.